Share Name Share Symbol Market Type
Sanofi EU:SAN Euronext Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.49 -2.73% 88.87 88.87 89.95 90.90 88.83 90.50 2,739,624 16:39:37

Sanofi Says Sutimlimab Trial Meets Endpoints

10/12/2019 1:27pm

Dow Jones News

Sanofi (EU:SAN)
Historical Stock Chart

2 Months : From Nov 2019 to Jan 2020

Click Here for more Sanofi Charts.

By Michael Dabaie


Sanofi SA (SNY) said a Phase 3 trial of sutimlimab in people with primary cold agglutinin disease met its primary and secondary endpoints.

The primary efficacy outcome was a responder rate based on a composite of an increase in hemoglobin from baseline or reaching a hemoglobin level at the 26-week assessment timepoint, and the absence of transfusions from Weeks 5 to 26.

Results also demonstrated rapid inhibition of hemolysis and clinically significant improvements in anemia and fatigue within one week of treatment, the company said.

Sanofi said it plans a U.S. Food and Drug Administration submission in the near future.


Write to Michael Dabaie at


(END) Dow Jones Newswires

December 10, 2019 08:12 ET (13:12 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

1 Year Sanofi Chart

1 Year Sanofi Chart

1 Month Sanofi Chart

1 Month Sanofi Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20200122 22:48:24